The main treatments for psoriatic arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), which can be either a traditional or a biologic ...

Treatment targets & strategies Remission, or at least minimal disease activity, should be the target of all treatment strategies in psoriatic arthritis. All musculoskeletal and cutaneous ...

Bimekizumab, as I mentioned, currently has FDA approval for psoriasis, but we are hoping to see that become available for psoriatic arthritis and axial spondyloarthritis, as well.

Commonly used medications are ... can talk about and decide on whether a biologic is the right treatment for your psoriatic arthritis. Biologics are recommended for those living with moderate ...

New study shows a subset of psoriatic arthritis patients can achieve long-term remission without DMARDs. Learn who benefits ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory ... exactly where diagnostic delays are occurring and the treatments people are receiving. The results confirm a ...

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...